CTIS2023-508177-85-00招募中1 期
A parallel-group, prevention, Phase 3, modified double-blind, 2-arm, study to investigate the immunogenicity and describe the safety of a quadrivalent meningococcal conjugate vaccine (MenACYW conjugate vaccine) compared with Nimenrix® when administered in a 1+1 schedule in healthy infants and toddlers at 6 and 12 months of age - MEQ00089
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Aged 6 to 7 months on the day of inclusion, Participants who are healthy as determined by medical evaluation including medical history, physical examination and judgment of the Investigator
排除标准
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within the past 3 months, History of meningococcal infection, confirmed either clinically, serologically, or microbiologically, At high risk for meningococcal infection during the study (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease), Personal history of Guillain-Barré syndrome, Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine, Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention(s) used in the study or to a product containing any of the same substances, Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature = 38.0°C [= 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided, Receipt of any vaccine (including COVID-19) and Meningococcal B vaccines) in the 4 weeks preceding the first and second study intervention administration or planned receipt of any vaccine (including COVID-19 and Meningococcal B vaccines) in the 4 weeks following any study intervention administration except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after the study interventions. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines., Previous vaccination against meningococcal A, C, W, or Y disease with either the trial vaccine or another vaccine (i.e., mono- or quadrivalent meningococcal conjugate vaccine) containing serogroups A, C, Y, or W.
研究者
相似试验
招募中
3 期
Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and OlderCTRI/2021/06/034442Sanofi Healthcare India Private Limited
尚未招募
3 期
VAT00008: A parallel-group, Phase III, multi-stage, modified double-blind, Placebo-Controlled, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent- CoV2 preS dTM-AS03 (D614) and bivalent CoV2 preS dTM-AS03 (D614 + B.1.351)) for prevention against COVID-19 in adults 18 years of age and older.COVID-19SLCTR/2021/026Sanofi Pasteur Inc.
进行中（未招募）
1 期
A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (leuprorelin 3.75mg) for pre-operative treatment of symptomatic uterine myomas. - PEARL II, PGL4001 versus GnRH-agonist in uterine myomasterine myomas are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asymptomatic. When symptomatic, its cardinal symptoms are heavy uterine bleeding, anaemia, abdominal pressure, abdominal pain, urinary frequency and infertility. Myomas affect approximately 40% of women between 35 and 55 years.MedDRA version: 9.1Level: LLTClassification code 10046801Term: Uterine myomaEUCTR2008-001805-40-FRPregLem S.A.300
进行中（未招募）
不适用
A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (leuprorelin 3.75mg) for pre-operative treatment of symptomatic uterine myomas. - PEARL II, PGL4001 versus GnRH-agonist in uterine myomasterine myomas are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asymptomatic. When symptomatic, its cardinal symptoms are heavy uterine bleeding, anaemia, abdominal pressure, abdominal pain, urinary frequency and infertility. Myomas affect approximately 40% of women between 35 and 55 years.MedDRA version: 9.1Level: LLTClassification code 10046801Term: Uterine myomaEUCTR2008-001805-40-PLPregLem S.A.300
进行中（未招募）
不适用
A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (leuprorelin 3.75mg) for pre-operative treatment of symptomatic uterine myomas. - PEARL IIsymptomatic uterine myomaMedDRA version: 9.1Level: LLTClassification code 10046801Term: Uterine myomaEUCTR2008-001805-40-ITPREGLEM SA300